Jan Lycke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6172109/publications.pdf

Version: 2024-02-01

96 papers	8,086 citations	81743 39 h-index	51492 86 g-index
99 all docs	99 docs citations	99 times ranked	9290 citing authors

#	Article	IF	Citations
1	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
2	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
3	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
4	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 2020, 77, 184.	4.5	342
5	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 2017, 89, 2230-2237.	1.5	307
6	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Annals of Neurology, 2011, 69, 83-89.	2.8	295
7	Rituximab in multiple sclerosis. Neurology, 2016, 87, 2074-2081.	1.5	278
8	Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology, 2003, 61, 1720-1725.	1.5	276
9	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
10	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	4.9	238
11	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
12	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
13	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology, 2016, 79, 950-958.	2.8	190
14	High nationwide prevalence of multiple sclerosis in Sweden. Multiple Sclerosis Journal, 2011, 17, 901-908.	1.4	163
15	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal, 2018, 24, 1046-1054.	1.4	149
16	Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1116-1121.	0.9	139
17	Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. Journal of Neurology, 2011, 258, 882-888.	1.8	131
18	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304.	2.1	124

#	Article	IF	Citations
19	Acyclovir treatment of relapsing-remitting multiple sclerosis. Journal of Neurology, 1996, 243, 214-224.	1.8	112
20	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12952-12960.	3.3	102
21	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 43-50.	1.4	101
22	A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 708-719.	1.4	98
23	Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. Journal of the Neurological Sciences, 1995, 133, 61-65.	0.3	94
24	Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. Acta Neurologica Scandinavica, 1990, 82, 161-168.	1.0	91
25	Acyclovir Levels in Serum and Cerebrospinal Fluid after Oral Administration of Valacyclovir. Antimicrobial Agents and Chemotherapy, 2003, 47, 2438-2441.	1.4	90
26	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 1197.	4.5	90
27	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 2020, 94, e1201-e1212.	1.5	88
28	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	2.8	86
29	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	1.4	81
30	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Multiple Sclerosis Journal, 2016, 22, 1587-1595.	1.4	73
31	Smouldering multiple sclerosis: the â€˜real MSâ€™. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110667.	1.5	72
32	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Multiple Sclerosis Journal, 2013, 19, 765-774.	1.4	66
33	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	4.9	64
34	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.5	61
35	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. Acta Neurologica Scandinavica, 2017, 135, 17-24.	1.0	57
36	Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Multiple Sclerosis Journal, 2016, 22, 212-221.	1.4	56

#	Article	IF	Citations
37	CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. Journal of Neuroimmunology, 2014, 269, 87-89.	1.1	51
38	High Nationwide Incidence of Multiple Sclerosis in Sweden. PLoS ONE, 2014, 9, e108599.	1.1	51
39	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	4.9	45
40	Rituximab in paediatric onset multiple sclerosis: a case series. Journal of Neurology, 2016, 263, 322-326.	1.8	42
41	Minocycline added to subcutaneous interferon Î²â€1a in multiple sclerosis: randomized <scp>RECYCLINE</scp> study. European Journal of Neurology, 2016, 23, 861-870.	1.7	41
42	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	1.4	39
43	Acyclovir concentrations in serum and cerebrospinal fluid at steady state. Journal of Antimicrobial Chemotherapy, 1989, 24, 947-954.	1.3	37
44	Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Therapeutic Advances in Neurological Disorders, 2015, 8, 274-293.	1.5	37
45	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS ONE, 2018, 13, e0194828.	1.1	32
46	Peripheral neuropathy associated with monoclonal IgM antibody to glycolipids with a terminal glucuronyl-3-sulfate epitope. Journal of Neurology, 1993, 240, 381-387.	1.8	29
47	Asymptomatic visual loss in multiple sclerosis. Journal of Neurology, 2001, 248, 1079-1086.	1.8	27
48	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology, 2019, 26, 1060-1067.	1.7	27
49	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A realâ€world investigation. Journal of Neurochemistry, 2021, 159, 618-628.	2.1	26
50	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsingâ€“remitting multiple sclerosis: an observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 189-194.	0.9	25
51	Trials of antivirals in the treatment of multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 45-48.	1.0	24
52	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-BarrÃ© syndrome: A pilot study. Acta Neurologica Scandinavica, 2018, 138, 143-150.	1.0	24
53	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. Journal of the Neurological Sciences, 2015, 358, 201-206.	0.3	22
54	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. Journal of Neuroinflammation, 2019, 16, 16.	3.1	22

#	Article	IF	Citations
55	The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Review of Clinical Immunology, 2017, 13, 1143-1153.	1.3	20
56	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. Multiple Sclerosis and Related Disorders, 2020, 46, 102463.	0.9	20
57	Age-dependent effects on the treatment response of natalizumab in MS patients. Multiple Sclerosis Journal, 2015, 21, 48-56.	1.4	19
58	High Interferon-Î³ Uniquely in VÎ´1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 260.	2.2	19
59	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis Journal, 2020, 26, 1866-1876.	1.4	16
60	<scp>SARSâ€COV</scp>â€2 a trigger of myelin oligodendrocyte glycoproteinâ€associated disorder. Annals of Clinical and Translational Neurology, 2022, 9, 1296-1301.	1.7	16
61	First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. Journal of Neurology, 2014, 261, 2016-2018.	1.8	14
62	Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. Journal of the Neurological Sciences, 2015, 353, 155-157.	0.3	14
63	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive <scp>MS</scp> from relapsingâ€remitting <scp>MS</scp>. Journal of Neurochemistry, 2018, 146, 322-332.	2.1	14
64	No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis. Annals of Neurology, 1992, 32, 711-714.	2.8	13
65	Efficacy of alemtuzumab over 6â€‰years in relapsingâ€“remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. Multiple Sclerosis Journal, 2020, 26, 1719-1728.	1.4	13
66	Human spumaretrovirus antibody reactivity in multiple sclerosis. Journal of Neurology, 1994, 241, 204-209.	1.8	11
67	Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29. Journal of the Neurological Sciences, 2016, 370, 123-131.	0.3	11
68	An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3565-3572.	1.3	10
69	Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers. Clinical Chemistry, 2020, 66, 1228-1237.	1.5	10
70	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Multiple Sclerosis Journal, 2022, 28, 872-884.	1.4	10
71	A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland. Journal of Neurology, 2018, 265, 108-114.	1.8	9
72	Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology, 2021, 96, e1574-e1584.	1.5	9

#	Article	IF	Citations
73	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Multiple Sclerosis Journal, 2020, 26, 1532-1539.	1.4	8
74	Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092946.	1.5	8
75	Possible association of HTLV-I infection and dementia. Acta Neurologica Scandinavica, 2009, 88, 199-203.	1.0	7
76	Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis. Neuroepidemiology, 2015, 45, 83-89.	1.1	7
77	Cerebrospinal fluid NCAM levels are modulated by diseaseâ€modifying therapies. Acta Neurologica Scandinavica, 2019, 139, 422-427.	1.0	6
78	The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. Journal of Neurology, 2021, 268, 3316-3324.	1.8	6
79	Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance. Multiple Sclerosis and Related Disorders, 2021, 50, 102842.	0.9	6
80	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. Scientific Reports, 2019, 9, 17309.	1.6	5
81	MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. Journal of the Neurological Sciences, 2022, 439, 120320.	0.3	5
82	Use of immunoreactive synthetic HTLV-1 peptides in the search for antibody reactivity in multiple sclerosis. Acta Neurologica Scandinavica, 1992, 85, 44-54.	1.0	4
83	Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago. Multiple Sclerosis and Related Disorders, 2020, 44, 102253.	0.9	3
84	Autism spectrum disorders: does cilia dysfunction in embryogenesis play a role?. Acta Neuropsychiatrica, 2008, 20, 227-228.	1.0	2
85	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2021, 10, 803-818.	1.4	2
86	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. Multiple Sclerosis and Related Disorders, 2021, 52, 102977.	0.9	2
87	Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden. Journal of Medical Economics, 2021, 24, 770-780.	1.0	1
88	Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210903.	1.5	1
89	PO152â€…Alemtuzumab efficacy in patients with relapse after course 1. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A53.1-A53.	0.9	0
90	A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2. Canadian Journal of Neurological Sciences, 2018, 45, S10-S10.	0.3	0

#	Article	IF	Citations
91	P.027 Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses. Canadian Journal of Neurological Sciences, 2018, 45, S23-S23.	0.3	0
92	054â€…Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A22.2-A22.	0.9	0
93	Improvements Across Functional Systems Are Maintained Regardless of Early VS Late Confirmed Disability Improvement: CARE-MS 6-Year Follow-Up. Multiple Sclerosis and Related Disorders, 2020, 37, 101587.	0.9	0
94	Efficacy of a Fourth Alemtuzumab Course in RRMS Patients from CARE-MS II Who Experienced Disease Activity After Three Prior Courses. Multiple Sclerosis and Related Disorders, 2020, 37, 101585.	0.9	0
95	The Effect of Different National Treatment Strategies on Disability Outcome in Relapsing-Remitting Multiple Sclerosis: A Propensity Score Adjusted Comparison between Denmark and Sweden. SSRN Electronic Journal, 0, , .	0.4	0
96	Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary. Multiple Sclerosis Journal, 2022, 28, 1177-1178.	1.4	0